KCM Investment Advisors LLC Sells 2,315 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

KCM Investment Advisors LLC trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,842 shares of the medical equipment provider’s stock after selling 2,315 shares during the quarter. KCM Investment Advisors LLC’s holdings in Zimmer Biomet were worth $3,892,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Franklin Resources Inc. grew its position in Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock valued at $369,469,000 after purchasing an additional 2,796,372 shares during the last quarter. Norges Bank bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $216,223,000. Sound Shore Management Inc. CT purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $81,447,000. Equity Investment Corp lifted its position in Zimmer Biomet by 57.2% in the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider’s stock valued at $107,855,000 after acquiring an additional 371,653 shares in the last quarter. Finally, Van ECK Associates Corp boosted its stake in Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after purchasing an additional 218,688 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research analyst reports. Stifel Nicolaus upped their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Finally, Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Trading Down 4.6 %

Shares of ZBH stock opened at $107.46 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock has a fifty day simple moving average of $107.32 and a two-hundred day simple moving average of $107.21. The firm has a market capitalization of $21.39 billion, a PE ratio of 24.15, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $129.50.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the previous year, the company earned $2.20 earnings per share. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s payout ratio is 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.